Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
BofA likes Johnson & Johnson in premarket analyst action
11:38am, Wednesday, 22'nd Apr 2020
Adaptimmune (NASDAQ:ADAP) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities.Autolus Therapeutics (NASDAQ:AUTL) initiated with Buy rating and $18 (90% upside) p
Nektar initiated with a Buy at Benchmark NKTR
11:15am, Wednesday, 22'nd Apr 2020
Nektar initiated with a Buy at Benchmark Benchmark NKTR
Exane Derivatives Sells 11,246 Shares of Nektar Therapeutics (NASDAQ:NKTR)
10:20am, Tuesday, 21'st Apr 2020
Exane Derivatives lessened its stake in Nektar Therapeutics (NASDAQ:NKTR) by 79.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund o
Nektar Therapeutics (NASDAQ:NKTR) Director Sells $147,040.00 in Stock
09:16am, Monday, 20'th Apr 2020
Nektar Therapeutics (NASDAQ:NKTR) Director Robert Chess sold 8,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $18.38, for a total value of
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.44%
12:00am, Monday, 20'th Apr 2020
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.44%
2 Biotechs Battling Against Kidney Cancer
12:10pm, Saturday, 18'th Apr 2020
New combination trials bring hope for patients and investors.
Mizuho Securities Thinks Xeris Pharmaceuticals' Stock is Going to Recover
12:35pm, Friday, 17'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $18.00. The company's shares
Mizuho Securities Thinks Xeris Pharmaceuticals’ Stock is Going to Recover
12:35pm, Friday, 17'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a
Bank of America Corp DE Sells 155,174 Shares of Nektar Therapeutics (NASDAQ:NKTR)
08:42am, Thursday, 16'th Apr 2020
Bank of America Corp DE lowered its position in Nektar Therapeutics (NASDAQ:NKTR) by 47.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange
RemeGen candidate Fast Track'd for lupus
03:13pm, Wednesday, 15'th Apr 2020
The FDA has signed off on Fast Track status for Yantai, China-based RemeGen's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE).RC18 (telitacicept) is a recombinant TACI-F
NYC reaches deal on seeking board, CEO diversity at 13 companies
07:11pm, Tuesday, 14'th Apr 2020Urban Gardening: Machen Sie die Welt ein wenig grüner - Blick
02:34pm, Monday, 13'th Apr 2020
«Urban Gardening» nennt sich der erdige Trend der letzten Jahre, der unentwegt anhält. In der jetzigen Zeit, wo man den ganzen Tag zu Hause bleiben muss, der richtige Zeitpunkt für dieses Projekt.
Nektar Therapeutics (NASDAQ:NKTR) Expected to Post Quarterly Sales of $45.00 Million
08:44am, Monday, 13'th Apr 2020
Brokerages forecast that Nektar Therapeutics (NASDAQ:NKTR) will post $45.00 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estima
Mizuho Securities Thinks Xeris Pharmaceuticals' Stock is Going to Recover
02:00am, Monday, 13'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) yesterday and set a price target of $18.00. The company's
